Trial Profile
A Phase II Evaluation of Abraxane Plus Bevacizumab for the Treatment of Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2013
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 06 Apr 2013 New trial record